Farther Finance Advisors’s Stoke Therapeutics STOK Stock Holding History

Farther Finance Advisors’s Portfolio STOK Stock Details STOK Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q3	$442	Hold	17	–	–	﹤0.01%	5774
2026 Q2	$556	Sell	17 -23	-58%	-$738	﹤0.01%	5512
2026 Q1	$1.28K	Buy	40 +22	+122%	+$721	﹤0.01%	5036
2025 Q4	$571	Buy	18 +1	+6%	+$30	﹤0.01%	5029
2025 Q3	$400	Buy	17 +10	+143%	+$171	﹤0.01%	4593
2025 Q2	$79	Hold	7	–	–	﹤0.01%	4333
2025 Q1	$44	Hold	7	–	–	﹤0.01%	4135
2024 Q4	$77	Hold	7	–	–	﹤0.01%	3827
2024 Q3	$86	Buy	+7	New	+$99	﹤0.01%	3806

Other funds holding STOK

VCM

Versant Capital Management Phoenix, Arizona $1.17B AUM 28.44% 1-Year Est. Return

GAMMA Investing Foster City, California $2.96B AUM 34.38% 1-Year Est. Return

Farther Finance Advisors's STOK Position: Q3 2026 in Review

Farther Finance Advisors held its Stoke Therapeutics (STOK) position steady in Q3 2026 at 17 shares worth $442. The position accounts for ﹤0.01% of the portfolio, ranked #5774.

Farther Finance Advisors first reported a position in STOK in Q3 2024 and has held it in 9 quarters since. The position peaked at $1.28K in Q1 2026. 3 funds tracked by Wall St. Rank hold STOK as of Q3 2026.

Farther Finance Advisors held 17 shares of Stoke Therapeutics worth $442 as of Q3 2026.
Farther Finance Advisors left its Stoke Therapeutics share count unchanged in Q3 2026.
Stoke Therapeutics made up ﹤0.01% of Farther Finance Advisors's portfolio in Q3 2026, its #5774 holding.
Farther Finance Advisors first reported a position in Stoke Therapeutics in Q3 2024 and has held it in 9 quarters since.
Farther Finance Advisors's Stoke Therapeutics position peaked at $1.28K in Q1 2026.
3 funds tracked by Wall St. Rank held Stoke Therapeutics as of Q3 2026.

Based on Farther Finance Advisors's 13F filing for Q3 2026, filed 8 Oct 2026.